293 related articles for article (PubMed ID: 20587412)
21. A survey of the clinicopathological and molecular characteristics of patients with suspected Lynch syndrome in Latin America.
Rossi BM; Palmero EI; López-Kostner F; Sarroca C; Vaccaro CA; Spirandelli F; Ashton-Prolla P; Rodriguez Y; de Campos Reis Galvão H; Reis RM; Escremim de Paula A; Capochin Romagnolo LG; Alvarez K; Della Valle A; Neffa F; Kalfayan PG; Spirandelli E; Chialina S; Gutiérrez Angulo M; Castro-Mujica MDC; Sanchez de Monte J; Quispe R; da Silva SD; Rossi NT; Barletta-Carrillo C; Revollo S; Taborga X; Morillas LL; Tubeuf H; Monteiro-Santos EM; Piñero TA; Dominguez-Barrera C; Wernhoff P; Martins A; Hovig E; Møller P; Dominguez-Valentin M
BMC Cancer; 2017 Sep; 17(1):623. PubMed ID: 28874130
[TBL] [Abstract][Full Text] [Related]
22. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
[TBL] [Abstract][Full Text] [Related]
23. Clinical and Molecular Characterization of Brazilian Patients Suspected to Have Lynch Syndrome.
Carneiro da Silva F; Ferreira JR; Torrezan GT; Figueiredo MC; Santos ÉM; Nakagawa WT; Brianese RC; Petrolini de Oliveira L; Begnani MD; Aguiar-Junior S; Rossi BM; Ferreira Fde O; Carraro DM
PLoS One; 2015; 10(10):e0139753. PubMed ID: 26437257
[TBL] [Abstract][Full Text] [Related]
24. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
25. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome).
Hendriks YM; Jagmohan-Changur S; van der Klift HM; Morreau H; van Puijenbroek M; Tops C; van Os T; Wagner A; Ausems MG; Gomez E; Breuning MH; Bröcker-Vriends AH; Vasen HF; Wijnen JT
Gastroenterology; 2006 Feb; 130(2):312-22. PubMed ID: 16472587
[TBL] [Abstract][Full Text] [Related]
26. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
[TBL] [Abstract][Full Text] [Related]
27. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.
Piñol V; Castells A; Andreu M; Castellví-Bel S; Alenda C; Llor X; Xicola RM; Rodríguez-Moranta F; Payá A; Jover R; Bessa X;
JAMA; 2005 Apr; 293(16):1986-94. PubMed ID: 15855432
[TBL] [Abstract][Full Text] [Related]
28. Genomic rearrangements in MSH2, MLH1 or MSH6 are rare in HNPCC patients carrying point mutations.
Pistorius S; Görgens H; Plaschke J; Hoehl R; Krüger S; Engel C; Saeger HD; Schackert HK
Cancer Lett; 2007 Apr; 248(1):89-95. PubMed ID: 16837128
[TBL] [Abstract][Full Text] [Related]
29. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
[TBL] [Abstract][Full Text] [Related]
30. Review article: The Lynch syndrome (hereditary nonpolyposis colorectal cancer).
Vasen HF
Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():113-26. PubMed ID: 18081655
[TBL] [Abstract][Full Text] [Related]
31. Lynch syndrome in the 21st century: clinical perspectives.
Tiwari AK; Roy HK; Lynch HT
QJM; 2016 Mar; 109(3):151-8. PubMed ID: 26224055
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemistry identifies carriers of mismatch repair gene defects causing hereditary nonpolyposis colorectal cancer.
Stormorken AT; Bowitz-Lothe IM; Norèn T; Kure E; Aase S; Wijnen J; Apold J; Heimdal K; Møller P
J Clin Oncol; 2005 Jul; 23(21):4705-12. PubMed ID: 16034045
[TBL] [Abstract][Full Text] [Related]
33. Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree.
Wagner A; Hendriks Y; Meijers-Heijboer EJ; de Leeuw WJ; Morreau H; Hofstra R; Tops C; Bik E; Bröcker-Vriends AH; van Der Meer C; Lindhout D; Vasen HF; Breuning MH; Cornelisse CJ; van Krimpen C; Niermeijer MF; Zwinderman AH; Wijnen J; Fodde R
J Med Genet; 2001 May; 38(5):318-22. PubMed ID: 11333868
[TBL] [Abstract][Full Text] [Related]
34. Systematic study on genetic and epimutational profile of a cohort of Amsterdam criteria-defined Lynch Syndrome in Singapore.
Liu Y; Chew MH; Goh XW; Tan SY; Loi CT; Tan YM; Law HY; Koh PK; Tang CL
PLoS One; 2014; 9(4):e94170. PubMed ID: 24710284
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening.
Urakami S; Inoshita N; Oka S; Miyama Y; Nomura S; Arai M; Sakaguchi K; Kurosawa K; Okaneya T
Int J Urol; 2018 Feb; 25(2):151-156. PubMed ID: 29164703
[TBL] [Abstract][Full Text] [Related]
36. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
[TBL] [Abstract][Full Text] [Related]
37. [Genetic analysis of 45 patients with suspected Lynch syndrome using next-generation sequencing].
Yao ZG; Cheng XK; Lin CH; Li J; Lyu BB; Li JM; Jing HY; Qin YJ; Sun XC
Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):843-849. PubMed ID: 34407589
[No Abstract] [Full Text] [Related]
38. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).
Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Nakagawa H; Sotamaa K; Prior TW; Westman J; Panescu J; Fix D; Lockman J; Comeras I; de la Chapelle A
N Engl J Med; 2005 May; 352(18):1851-60. PubMed ID: 15872200
[TBL] [Abstract][Full Text] [Related]
39. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium.
Plaschke J; Engel C; Krüger S; Holinski-Feder E; Pagenstecher C; Mangold E; Moeslein G; Schulmann K; Gebert J; von Knebel Doeberitz M; Rüschoff J; Loeffler M; Schackert HK
J Clin Oncol; 2004 Nov; 22(22):4486-94. PubMed ID: 15483016
[TBL] [Abstract][Full Text] [Related]
40. Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.
Kariola R; Raevaara TE; Lönnqvist KE; Nyström-Lahti M
Hum Mol Genet; 2002 May; 11(11):1303-10. PubMed ID: 12019211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
